WOCKPHARMA - Swing Trade Analysis with AI Signals

Last Updated Time : 05 Nov 25, 7:43 am

Swing Trade Rating: 3.2

📊 WOCKPHARMA presents a speculative swing trade setup with strong earnings rebound but weak technicals and valuation concerns. Optimal entry is ₹1,350–₹1,365. If already held, consider exiting near ₹1,410–₹1,430.

📈 Positive

• Qtr Profit Var of 250% shows a sharp earnings rebound.
• EPS of ₹8.68 supports improving profitability.
• Trading near 200-DMA (₹1,412) offers a potential resistance target.
• Debt-to-equity ratio (0.76) is manageable for a pharma company.

⚠️ Limitation

• MACD (-31.8) and RSI (48.4) suggest weak momentum and lack of bullish confirmation.
• P/E (157) is extremely high compared to industry average (33.1), indicating overvaluation.
• PEG ratio (6.50) implies expensive pricing relative to growth.
• ROCE (4.40%) and ROE (-0.53%) reflect poor capital efficiency and negative shareholder returns.
• Volume significantly below 1-week average may indicate reduced market interest.

🚫 Company Negative News

• FII holdings declined by 0.19%, showing reduced foreign investor confidence.
• Quarterly PAT dropped from ₹69.0 Cr. to ₹54.0 Cr., indicating earnings volatility.
• Stock has corrected over 27% from its 52-week high of ₹1,870.

✅ Company Positive News

• Despite the recent PAT drop, the prior quarter’s surge suggests potential for cyclical recovery.
• Stable domestic institutional holding and brand presence in pharma support long-term potential.

🌐 Industry

• WOCKPHARMA operates in the pharmaceutical sector, which benefits from healthcare demand and export opportunities.
• Industry P/E of 33.1 reflects moderate valuation expectations.

🧾 Conclusion

• WOCKPHARMA is a speculative swing trade candidate with earnings momentum but weak technicals and valuation risks.
• Optimal entry: ₹1,350–₹1,365 (near current support zone).
• Exit target: ₹1,410–₹1,430 (near 200-DMA and resistance).
• Watch for MACD reversal and RSI crossing 50 to confirm momentum.

I can help you compare WOCKPHARMA’s setup with other pharma stocks to identify stronger swing trade opportunities.